Citation: piotr nikodem rudzinski, markus mach, christoph gross, marco russo, paul werner, iuliana coti, sabine scherzer, martin andreas.Current prostheses for transcatheter heart valve replacement: a technical and clinical review.Rev.Cardiovasc.Med.2022, 23(8), 257.Https://doi.Org/10.31083/j.Rcm2308257 a copy of the article was not attached as digital sharing would be in violation of copyright permission.Earliest date of publication used for date of event.Medtronic products referenced: corevalve (product code npt, pma# p130021), evolut r (product code npt, pma# p130021), evolut pro (product code npt, pma# p130021), evolut pro+ (product code npt, pma# p130021).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product, no definitive conclusion can be made regarding the clinical observations.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
Literature was reviewed regarding a technical and clinical review of current prostheses used for transcatheter aortic valve replacement (tavr).In figure 4, the authors presented an image and text concerning a surgically explanted self-expanding valve that appears to be a medtronic valve type (corevalve, evolut r, evolut pro, or evolut pro+).It was stated that the self-expanding valve showed structural valve deterioration in form of a commissural leaflet tear which led to severe transvalvular regurgitation, while pannus ingrowth was noted on the aortic side of the valve.The valve was explanted approximately 24 months after implantation.No further details were disclosed about this case.
|